Menu
← Oncology Approval Tracker
FDA DECISION ·
Vyxeos
daunorubicin and cytarabine liposome · Jazz Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Expansion to patients as young as 1 year with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.
LAMPGEN ANALYSIS
Why it matters
The action extends a fixed-ratio liposomal regimen into defined pediatric secondary AML populations.
What research teams should watch
Verify age, AML subtype and treatment history, and align pediatric safety and dosing documentation.
PRIMARY RECORDS